Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $32 to $36.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.